Investors
Corporate Profile
Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Stock Information
Financial Market Data powered by Quotemedia. All rights reserved.
View the Terms of Use. Data delayed 15 minutes unless indicated.
ISIN: BE0974260896-XBRU Updated at
Financial Calendar
Mar 23, 2023
FY 2022 Financial Results
May 5, 2023
- Annual Shareholder Meeting
- Q1 2023 Business Update
Aug 3, 2023
H1 2023 Interim Results
Nov 9, 2023
Q3 2023 Business Update
Investors Kit
Corporate Presentation
Annual Report 2022
Upcoming Events
Sorry, no posts matched your criteria.